Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MDU Resources Group Inc. Common Stock (Holding Company) (MDU) vs NeoGenomics Inc. Common Stock (NEO) Price & Performance

MDU Resources Group Inc. Common Stock (Holding Company)Trade
NeoGenomics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

MDU Resources Group Inc. Common Stock (Holding Company) vs NeoGenomics Inc. Common Stock — how do they compare? MDU Resources Group Inc. Common Stock (Holding Company) trades at $18.56 (market cap $3.92B), while NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.14B). The key difference: MDU Resources Group Inc. Common Stock (Holding Company) is the larger of the two by market cap, and MDU Resources Group Inc. Common Stock (Holding Company) pays a 3.03% dividend while NeoGenomics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MDU Resources Group Inc. Common Stock (Holding Company) for 0 Days and NeoGenomics Inc. Common Stock for 0 Days on average.

MDUNEO
Market Cap
$3.92B$2.14B
Volume
1,027,6562,228,400
Sector
UtilitiesHealth
52-Week High
$22.80$19.91
52-Week Low
$18.39$7.19
Typical Hold Time
0 Days0 Days
Enterprise Value
$6.45B$2.44B
Dividend Yield
3.03%—

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MDU
100% Buy0% Sell
Avg holding period · 0 Days
NEO
100% Buy0% Sell
Avg holding period · 0 Days

About MDU Resources Group Inc. Common Stock (Holding Company)

MDU Resources Group, Inc. is a US holding company operating regulated electric and natural gas utility services alongside a construction materials and services business supplying asphalt, concrete, and aggregates.

Read more on MDU →

About NeoGenomics Inc. Common Stock

NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.

Read more on NEO →